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Abstract  Endovascular  aneurysm  repair  (EVAR)  is  indicated  in  high-risk  patients  for  con-
ventional  surgery,  with  anatomic  conditions  for  endoprosthesis  implantation.  Low  morbidity,
mortality  and  physiological  aggressiveness  have  been  expanding  the  indications  for  its  use.
Still, EVAR  is  questionable  in  younger  patients,  with  a  low  surgical  risk  and  a  prolonged  life
expectancy.  Abdominal  aortic  aneurysms  (AAA)  are  rare  in  human  immunodeﬁciency  virus  (HIV)
infected patients  in  western  countries  and  have  singular  characteristics:  an  unknown  etiology,
multiple arterial  involvement,  poor  open  surgery  results  and  risk  of  infection  transmission  to
surgeons. For  these  reasons  EVAR  opened  new  therapeutic  perspectives  in  this  group  of  patients.
We present  our  experience  with  two  HIV  patients  in  whom  an  AAA  was  diagnosed,  one  with  a
10 cm  diameter  treated  by  EVAR,  excluded  with  an  aorto-uni-iliac  endoprosthesis,  other  fol-
lowed regularly,  describing  their  features  and  therapeutic  results.  The  reported  cases  allow  us
to speculate  on  the  importance  of  anti-retroviral  and  endovascular  treatments  reducing  the
inﬂammatory  process  on  the  arterial  wall,  with  a  consequent  delay  in  aneurysm  growth  and
even its  regression,  which  reinforces  the  possible  relevance  of  EVAR  as  a  ﬁrst  line  treatment
for this  particular  pathology.sa  de  Angiologia  e  Cirurgia  Vascular.  Published  by  Elsevier  Espan˜a,
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Aneurisma  da  aorta  abdominal  e  infec¸ão pelo  vírus  da  imunodeﬁciência  humana,  uma
nova  indicac¸ão  para  tratamento  endovascular  do  aneurisma  da  aorta?
Resumo  O  tratamento  endovascular  do  aneurisma  da  aorta  (EVAR)  está  indicado  em  doentes  de
alto risco  cirúrgico  e  com  condic¸ões  anatómicas  favoráveis  para  implantac¸ão  da  endoprótese.
As reduzidas  morbimortalidade  e  agressividade  ﬁsiológica  desta  técnica  expandiram  as  suas
indicac¸ões, sendo  ainda  questionável  para  doentes  jovens,  de  baixo  risco  e  sobrevida  pro-
longada. A  associac¸ão  entre  aneurismas  da  aorta  abdominal  (AAA)  e  infec¸ão  vírus  da  imuno-
deﬁciência  humana  (HIV)  é  rara  no  mundo  ocidental,  tendo  ainda  várias  particularidades:  uma
etiologia desconhecida,  envolvimento  arterial  múltiplo,  maus  resultados  no  tratamento  por
cirurgia convencional  e  risco  de  transmissão  do  HIV.  Apresentamos  a  nossa  experiência  em  2
pacientes com  infec¸ão  HIV  e  AAA,  um  com  10  cm  de  diâmetro,  excluído  por  EVAR  com  endo-
prótese aorto-uni-ilíaca;  outro  seguido  regularmente,  descrevendo  as  suas  características  e
resultados. Estes  casos  permitem-nos  reﬂetir  sobre  a  importância  do  tratamento  antiretro-
vírico e  endovascular  na  reduc¸ão  do  processo  inﬂamatório  da  parede  arterial,  condicionando
um atraso  na  progressão  do  aneurisma  ou  mesmo  a  sua  regressão,  abrindo  perspetivas  para  uma
nova indicac¸ão  para  EVAR.
© 2016  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Publicado  por  Elsevier  Espan˜a,
en  Ac
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Introduction
Epidemic  infection  by  the  human  immunodeﬁciency  virus
(HIV)  continues  to  progress  despite  the  global  efforts  to
reduce  it.  The  largest  number  of  patients  with  HIV/AIDS  is
located  in  sub-Saharan  Africa  (60%  of  the  world’s  total)1,4
an  area  where  health  care  resources  are  scarce  and  access
to  anti-retroviral  treatment  is  limited.  In  this  disease,
non-atherosclerotic  vasculopathies,  in  which  aneurysms  are
included,  occur  at  a  later  stage  and  are  a  hallmark  of
advanced  disease,  and  that  may  be  the  reason  why  they  are
more  commonly  reported  in  Africa.1,6,8,9
The  treatment  of  abdominal  aortic  aneurysms  (AAA)
can  be  performed,  as  is  known,  by  conventional  surgery
Image  1  Pre-operative  CTA,  10  cm  i
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rcess  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.
r  endovascular  repair  (EVAR);  however,  it  is  still  a  mat-
er  of  dispute  in  this  pathology,  which  one  could  be
etter.  Aneurysms  associated  with  HIV  have  particular  char-
cteristics  and  pose  speciﬁc  problems:  the  etiology  is
nknown,  patient  life  expectancy  is  reduced  compared
o  the  general  population,  there  is  an  increased  infec-
ion  risk  due  to  immunosuppression  leading  to  poorer
hort  and  medium  term  conventional  surgery  results
nd  there  is  a  risk  of  HIV  infection  transmission  to
urgeons.
Treatment  with  highly  active  antiretroviral  therapynfra-renal  aorto-iliac  aneurysm.
HAART)  has  a proven  efﬁcacy  in  improving  overall  survival
y  inhibiting  viral  replication,10,14 but  its  effect  in  the  natu-
al  history  of  aneurysmal  disease  is  not  well  deﬁned.1,6--9,15
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e  present  two  case  reports  of  HIV  infected  patients  in
hom  an  AAA  was  diagnosed.
ase  1
 51-year-old  male  patient,  of  mixed  European  and  African
ncestry,  smoker,  with  hypertension  and  HIV  infection
etected  in  1999  following  the  diagnostic  work-up  for
sthenia.  The  infection  was  transmitted  by  sexual  inter-
ourse.  The  initial  results  of  laboratory  tests  showed  500,000
NA  copies/ml,  24  CD4+  T  lymphocytes  and  treatment
ith  HAART  was  initiated.  In  the  same  year,  the  patient
eveloped  atypical  mycobacteria  pneumonia  treated  with
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Image  3  9-month  post-operative  control  CTA,  d  ﬁnal  angiographic  control  after  EVAR.
ifampicin,  ethambutol  and  pyrazinamide.  In  2002,  he
ndured  weighty  personal  problems  that  led  him  to  aban-
on  HAART.  In  2005  he  had  an  acute  myocardial  infarction:
oronary  angiography  revealed  dilated  arteries  with  slow
ow  and  stenotic  disease  of  the  ﬁrst  marginal  artery,  not
menable  to  revascularization.
In  2008  he  was  admitted  to  the  emergency  depart-
ent  (ER)  with  diffuse  abdominal  pain  and  a  large  pulsatile
xpandable  abdominal  mass,  hypertension  and  anemia  (Hb
.8  g/dl).  A  CT  scan  of  the  abdomen  showed  an  infra-renal
orto-iliac  aneurysm  of  10  cm  diameter  and  no  rupture  evi-
ence  (Image  1).  At  that  moment  the  patient  had  14,731
NA  copies/ml  and  81  CD4+  T  lymphocytes.  He  was  trans-
erred  to  the  Department  of  Angiology  and  Vascular  Surgery
n  intravenous  perfusion  of  labetalol  for  blood  pressure
ontrol  and  resumed  HAART.  During  hospitalization  he  had
revealing  a  complete  aneurysm  regression.
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Image  4  18-month  post-operative  control  CTA,  showing  endo-
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numerous  episodes  of  abdominal  pain  associated  with  hyper-
tensive  crisis,  performing  several  CT’s  that  excluded  AAA
rupture.  Blood,  urine  and  sputum  cultures  were  negative
for  bacteria,  as  well  as  fungi  and  serological  tests  showed
presence  of  IgG  antibodies  for  Herpes  Simplex  1,  2  and
Varicella-Zoster  virus.
After  a  HAART  cycle,  which  allowed  a  decrease  of  the
viral  load  to  212  RNA  copies/ml,  EVAR  was  performed  under
general  anesthesia,  by  surgical  exposure  of  both  common
femoral  arteries.  An  aorto-uni-iliac  Endurant  Medtronic®
endoprosthesis  (with  a  proximal  diameter  of  28  mm  and  dis-
tal  diameter  of  24  mm)  was  implanted  through  the  right  iliac
axis,  followed  by  occlusion  of  the  common  and  external  left
iliac  arteries  (with  24  and  14  mm  occlusion  stents)  and  a
femoro-femoral  8  mm  PTFE  crossover  bypass  (Image  2).  The
option  for  the  mono-iliac  endoprosthesis  was  due  to  the
aneurysmal  extension  to  the  left  common  iliac  artery  and
severe  tortuosity  of  the  left  iliac  axis.  The  postoperative
period  was  complicated  by  an  ileus.
A  control  CT  performed  three  months  later  showed  no
endoleaks  and  at  9th  month  it  revealed  a  proper  sealing  and
a  complete  regression  of  the  aneurysm  with  a  good  match
between  the  endoprosthesis  and  native  arteries  (Image  3).
However,  at  18  months  the  patient  started  complaining  of
bilateral  intermittent,  non-disabling,  buttock  claudication
for  distances  of  500  meters,  without  palpable  pulses  in  the
lower  limbs.  A  CT  revealed  occlusion  of  the  endoprosthe-
sis  and  patency  of  the  femoro-femoral  crossover  bypass
(Image  4).  After  a  detailed  analysis  of  the  previous  CT  images
it  was  concluded  that  the  aneurysmal  regression  changed
the  endoprosthesis  conformation  within  the  common  iliac
artery,  leading  to  apposition  of  its  distal  end  to  the  arterial
wall,  a  fact  that  may  have  caused  its  occlusion.
In  2009  the  patient  was  admitted  to  the  ER  with  severe
headache  and  diagnosed  with  a  left  middle  cerebral  artery
aneurysm,  which  was  surgically  treated  using  a  Yasargyl
11  mm  clip.  The  postoperative  period  was  uneventful.  At  our
last  evaluation  he  still  has  stable  non-disabling  claudication,
without  any  evidence  of  aorto-iliac  aneurysm  in  control  CT’s.
Case  2
56  year-old  male,  Caucasian,  smoker,  with  hypertension  and
dyslipidemia.  He  had  syphilis  infection  twenty-three  years
earlier  and  two  myocardial  infarctions  in  1999  and  2004,
the  last  one  treated  with  percutaneous  revascularization  of
the  right  coronary  artery.  In  2000  he  was  diagnosed  with
HIV  infection,  transmitted  through  sexual  contact,  having  at
the  time  400,289  RNA  copies/ml  and  197  CD4+  HAART  was
initiated  resulting  in  a  decrease  in  RNA  counts  to  less  than
50/ml  and  CD4+  T  lymphocytes  increase  to  more  than  500.  In
2007,  in  a  routine  abdominal  ultrasound,  he  was  diagnosed
with  3.6  cm  diameter  AAA,  conﬁrmed  by  CT.  He  has  been
followed  regularly  as  an  outpatient,  asymptomatic,  with  a
stabilized  aneurysm  diameter  (Image  5).
DiscussionThe  occurrence  of  aneurysms  in  patients  with  HIV  infection,
particularly  in  the  aorta,  poses  several  particular  questions
concerning  its  etiology,  the  best  form  of  treatment  and  also
ethical  considerations.
s
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crosthesis  occlusion  and  patent  femoro-femoral  crossover
ypass.
Regarding  the  etiology,  they  can  be  secondary  to  a  bacte-
ial  or  fungal  infection  of  the  aortic  wall  or  of  a pre-existing
neurysm5,13 as  a  result  of  the  immunodeﬁciency.  They  can
lso  be  secondary  to  a  leukocytoclastic  vasculitis  of  the
eri-adventitial  blood  vessels’  and  vasa-vasorum  caused  by
n  HIV  direct  action  on  the  endothelium  or  by  deposi-
ion  of  immune-complexes.2,7,12 Regardless  of  the  etiology,
neurysms  associated  with  HIV  often  involve  multiple  arter-
es,  most  frequently  the  carotid  and  femoral  vessels  and
ore  commonly  younger  patients,  the  male  gender  and
frican  ancestry.6,8
The  ﬁrst  report  of  an  aneurysm  associated  with  HIV  comes
rom  by  Sinzobahamvya  in  Zimbabwe15 and  the  two  largest
ublished  series  in  the  literature  by  Robbs1 and  Botes9 are
rom  South  Africa  including  a  total  of  111  and  24  patients,
espectively.
From  an  ethical  point  of  view,  these  patients  should  be
ffered  the  best  treatment  available  and  simultaneously
he  one  that  has  a  less  likelihood  of  HIV  transmission  to
5urgeons.
The  best  therapy  is  not  yet  deﬁned.  The  results  of  con-
entional  surgery  are  dismal11 due  to  a  high  rate  of  infectious
omplications,  but  they  are  highly  dependent  on  multiple
114  R.  Machado  et  al.
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actors  such  as  the  CD4+  lymphocyte  count,  the  level  of
NA  copies,  the  serum  albumin  levels  and  type  of  transmis-
ion  (drug-addiction,  homosexual,  heterosexual  or  other).3
ndovascular  treatment,  as  a  less  aggressive  therapy,  with
ore  favorable  short-term  results,  may  have  a  particular
nterest  in  these  patients.  As  an  additional  advantage  it
llows  a  reduction  of  HIV  transmission  risk  to  the  surgical
eam  due  to  a  reduced  use  of  blades  and  needles,  reduced
ontact  with  open  surfaces,  less  blood  loss,  shorter  oper-
tive  time  and  hospitalization.  It  is  important  though,  to
till  take  into  account  general  measures  for  contamination
revention.
As  the  majority  of  the  AAAs  associated  with  HIV  are
eported  in  Africa,  where  EVAR  is  infrequently  performed
ue  to  less  resources,  there  cannot  be  withdrawn  any
onclusions  from  the  literature  concerning  the  utility  of
his  technique,  in  this  group  of  patients.  In  our  experi-
nce  with  these  two  patients,  we  could  observe  in  the
rst  case  a  complete  and  surprising  regression  of  a  10  cm
orto-iliac  aneurysm  nine  months  after  its  exclusion,  which
eads  us  to  speculate  that  associated  with  the  reduction
f  the  circulating  virus  load  by  HAART,  the  physical  barrier
f  the  endoprosthesis  between  arterial  wall  and  the  virus
nd/or  their  immune-complexes  might  have  conditioned  a
eduction  of  the  inﬂammatory  process,  with  a  subsequent
neurysm  regression.  In  the  second  case  we  can  also  spec-
late  that  the  maintenance  of  a  low  level  of  circulating
opies  of  HIV  RNA  by  HAART  could  be  responsible  for  the
tabilization  of  the  aneurysm  diameter.onclusions
he  HIV  infection  continues  to  progress  despite  the  efforts
ade  for  its  control.  The  clinical  consequences  are  likely  to
C
Tra-renal  AAA  diameter  (3.2  cm).
xpand,  particularly  in  the  vascular  territory,  in  the  form  of
neurysms,  which  are  late  manifestations  of  the  disease.
he  reported  cases  allow  us  to  speculate  on  the  impor-
ance  of  HAART  in  reducing  the  inﬂammatory  process  on
he  arterial  wall,  with  a consequent  delay  in  aneurysm
rowth  or  even  its  regression.  Our  option  for  an  endovas-
ular  treatment  in  the  ﬁrst  described  case  was  decided
fter  a  reﬂection  of  our  group  regarding  this  situation  and
ts  related  pathophysiology.  We  have  obtained  a complete
egression  of  a  large  10  cm  aorto-iliac  aneurysm,  which  rein-
orces  the  possible  relevance  of  EVAR  as  a  ﬁrst  line  treatment
or  this  particular  pathology.  It  is  however  necessary  to
cquire  more  experience  with  this  technique  in  this  subset
f  patients  and  call  for  publication  from  centers  with  larger
umber  of  patients  with  this  condition  so  that  more  clear
ata  can  be  obtained.
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